CLDF Title
Home | Contact Us | Bookmark
    HCC   HE   HRS   NASH   PBC   THROMBOCYTOPENIA  
Centers of Educational Expertise  
Live CME Meetings Webcasts Slide Library Abstract Library Conference Highlights
 
Back  
 
Reuters Health Information: Clopidogrel appropriate for PCI in liver transplant candidates

Clopidogrel appropriate for PCI in liver transplant candidates

Last Updated: 2020-01-07

By Reuters Staff

NEW YORK (Reuters Health) - In patients with decompensated cirrhosis undergoing percutaneous coronary intervention (PCI), clopidogrel safely inhibits platelet aggregation, according to a small study of liver-transplant candidates.

"Patients with advanced liver failure are often referred to a cardiologist to evaluate whether their cardiac function could withstand a liver-transplant surgery; however, there is very limited evidence about how best to treat patients in this scenario," said Dr. Cory R. Trankle of Virginia Commonwealth University in Richmond.

In particular, he told Reuters Health by email, "if the patients require a stent in their coronary artery . . . it is unclear whether the liver is able to activate certain medications in order to prevent that stent from thrombosing - which could have devastating consequences."

Dr. Trankle and colleagues studied 11 such patients with a median age of 63 years. Exclusion criteria included antiplatelet or anticoagulant medications other than aspirin and known coagulation abnormality unrelated to cirrhosis.

The patients received PCI and a clopidogrel loading dose of 600 mg orally, followed by maintenance therapy with aspirin 81 mg and clopidogrel 75 mg daily.

The median value of platelet reactivity units significantly decreased from baseline at all time points following clopidogrel load, with most patients responding two hours after the dose, the team reports in JACC: Cardiovascular Interventions.

Over the course of monitoring, there were no bleeding events, stent thrombosis, or acute coronary events during the period of dual antiplatelet therapy.

"Our study tested patients in this setting with a variety of sophisticated platelet assays and found that indeed the medication clopidogrel is working as it should," concluded Dr. Trankle.

"Further studies," he added, "are needed to determine the best strategy for cardiologists in seeing these types of patients, as the prevalence of certain forms of liver failure continues to rise."

SOURCE: https://bit.ly/2FtqXqY JACC: Cardiovascular Interventions, online December 25, 2019

 
 
 
 
                               
 
HEPATITIS
HBV
HCV
HDV
 
 
HCC
Slide Library
Abstract Library
 
HE
Webcasts
Slide Library
Abstract Library
 
HRS
Webcasts
Slide Library
Abstract Library
 
NASH
Webcasts
Slide Library
Abstract Library
 
 
PBC
Webcasts
Slide Library
Abstract Library
 
 
THROMBOCYTOPENIA
Webcasts
Slide Library
   
   
 
About CLDF
Mission Statement
Board of Trustees
Board of Advisors/Faculty
2019 GI Fellow Board of Advisors
 
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
 
Centers of
Educational Expertise
Hepatology
Substance Use Disorder
             
CLDF Follow Us
   
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2020 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.